Concepts (232)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Computer Simulation | 14 | 2019 | 637 | 2.340 |
Why?
|
| Software | 14 | 2019 | 677 | 2.310 |
Why?
|
| Models, Genetic | 9 | 2014 | 766 | 1.310 |
Why?
|
| Limonins | 1 | 2024 | 2 | 0.970 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2024 | 121 | 0.900 |
Why?
|
| Mouth Neoplasms | 1 | 2024 | 82 | 0.900 |
Why?
|
| Computational Biology | 5 | 2019 | 800 | 0.880 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2023 | 714 | 0.830 |
Why?
|
| Workflow | 2 | 2019 | 114 | 0.770 |
Why?
|
| Reactive Oxygen Species | 1 | 2024 | 477 | 0.760 |
Why?
|
| Apoptosis | 2 | 2024 | 1781 | 0.720 |
Why?
|
| Programming Languages | 2 | 2018 | 19 | 0.700 |
Why?
|
| Genetic Variation | 6 | 2014 | 1480 | 0.700 |
Why?
|
| Colonic Neoplasms | 1 | 2023 | 246 | 0.690 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2024 | 651 | 0.660 |
Why?
|
| Genome, Human | 9 | 2015 | 1266 | 0.600 |
Why?
|
| Genome-Wide Association Study | 9 | 2015 | 1641 | 0.520 |
Why?
|
| Biological Evolution | 4 | 2012 | 221 | 0.470 |
Why?
|
| Disease | 4 | 2014 | 130 | 0.470 |
Why?
|
| Alleles | 5 | 2015 | 1604 | 0.420 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2017 | 543 | 0.420 |
Why?
|
| Polymorphism, Single Nucleotide | 8 | 2015 | 2585 | 0.340 |
Why?
|
| Cell Proliferation | 5 | 2024 | 2307 | 0.340 |
Why?
|
| Cell Line, Tumor | 4 | 2024 | 3277 | 0.330 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2016 | 866 | 0.320 |
Why?
|
| Genetics, Population | 2 | 2010 | 189 | 0.320 |
Why?
|
| Algorithms | 3 | 2011 | 1595 | 0.310 |
Why?
|
| User-Computer Interface | 3 | 2019 | 153 | 0.300 |
Why?
|
| Cell Cycle | 2 | 2023 | 612 | 0.270 |
Why?
|
| Internet | 3 | 2018 | 378 | 0.260 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2019 | 237 | 0.260 |
Why?
|
| Sequence Analysis, DNA | 4 | 2016 | 1760 | 0.260 |
Why?
|
| Mice, Inbred NOD | 2 | 2023 | 285 | 0.250 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2024 | 51 | 0.240 |
Why?
|
| Mice, SCID | 2 | 2023 | 571 | 0.240 |
Why?
|
| Kidney Neoplasms | 2 | 2019 | 430 | 0.220 |
Why?
|
| Models, Statistical | 4 | 2014 | 474 | 0.220 |
Why?
|
| Molecular Sequence Annotation | 2 | 2015 | 144 | 0.210 |
Why?
|
| G1 Phase Cell Cycle Checkpoints | 1 | 2023 | 17 | 0.210 |
Why?
|
| Antineoplastic Agents | 2 | 2024 | 1677 | 0.210 |
Why?
|
| Humans | 32 | 2024 | 123146 | 0.200 |
Why?
|
| Genetic Association Studies | 3 | 2015 | 759 | 0.200 |
Why?
|
| Signal Transduction | 5 | 2024 | 4494 | 0.200 |
Why?
|
| Reproducibility of Results | 3 | 2019 | 2848 | 0.190 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2017 | 3083 | 0.190 |
Why?
|
| Proteinase Inhibitory Proteins, Secretory | 1 | 2020 | 7 | 0.170 |
Why?
|
| Histone Deacetylase 6 | 1 | 2019 | 7 | 0.170 |
Why?
|
| Sequence Analysis, RNA | 3 | 2018 | 376 | 0.170 |
Why?
|
| Hyperalgesia | 1 | 2019 | 25 | 0.170 |
Why?
|
| Epidermis | 1 | 2019 | 60 | 0.170 |
Why?
|
| Neuralgia | 1 | 2020 | 42 | 0.170 |
Why?
|
| Mitochondria | 1 | 2024 | 678 | 0.170 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2019 | 9 | 0.170 |
Why?
|
| Computing Methodologies | 1 | 2019 | 1 | 0.160 |
Why?
|
| Retinoblastoma Binding Proteins | 1 | 2018 | 10 | 0.160 |
Why?
|
| Isotope Labeling | 1 | 2019 | 102 | 0.160 |
Why?
|
| Stomatitis, Aphthous | 1 | 2018 | 3 | 0.160 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2019 | 128 | 0.150 |
Why?
|
| Eye Neoplasms | 1 | 2018 | 50 | 0.150 |
Why?
|
| Cisplatin | 1 | 2019 | 242 | 0.150 |
Why?
|
| Evolution, Molecular | 2 | 2013 | 672 | 0.150 |
Why?
|
| Mass Spectrometry | 1 | 2019 | 326 | 0.150 |
Why?
|
| Dermatomyositis | 2 | 2015 | 21 | 0.140 |
Why?
|
| Ureteral Neoplasms | 1 | 2017 | 24 | 0.140 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2017 | 49 | 0.140 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2017 | 35 | 0.140 |
Why?
|
| Kidney Pelvis | 1 | 2017 | 43 | 0.140 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 2017 | 80 | 0.140 |
Why?
|
| Research | 1 | 2019 | 263 | 0.140 |
Why?
|
| Urothelium | 1 | 2017 | 60 | 0.140 |
Why?
|
| Carcinoma, Lewis Lung | 1 | 2016 | 4 | 0.140 |
Why?
|
| Colorectal Neoplasms | 1 | 2023 | 560 | 0.140 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2017 | 149 | 0.140 |
Why?
|
| Serine Endopeptidases | 1 | 2017 | 175 | 0.130 |
Why?
|
| Paracrine Communication | 1 | 2016 | 71 | 0.130 |
Why?
|
| Multigene Family | 1 | 2017 | 298 | 0.130 |
Why?
|
| Genotype | 4 | 2014 | 2540 | 0.130 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2018 | 353 | 0.130 |
Why?
|
| Ureter | 1 | 2017 | 96 | 0.130 |
Why?
|
| Gene Frequency | 3 | 2014 | 713 | 0.130 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2017 | 269 | 0.130 |
Why?
|
| Fibroblasts | 1 | 2020 | 878 | 0.130 |
Why?
|
| Precancerous Conditions | 1 | 2018 | 287 | 0.120 |
Why?
|
| Myositis | 1 | 2015 | 51 | 0.120 |
Why?
|
| Papillomavirus Infections | 1 | 2018 | 278 | 0.120 |
Why?
|
| Mutation | 4 | 2018 | 5773 | 0.120 |
Why?
|
| Interleukin-6 | 1 | 2016 | 393 | 0.120 |
Why?
|
| Genomics | 3 | 2017 | 1477 | 0.120 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2017 | 531 | 0.120 |
Why?
|
| Biomarkers, Tumor | 3 | 2019 | 1432 | 0.120 |
Why?
|
| Neoplastic Stem Cells | 1 | 2016 | 294 | 0.120 |
Why?
|
| HLA Antigens | 1 | 2015 | 243 | 0.110 |
Why?
|
| Genotyping Techniques | 1 | 2014 | 101 | 0.110 |
Why?
|
| Quality Control | 1 | 2014 | 119 | 0.110 |
Why?
|
| Virus Integration | 1 | 2014 | 42 | 0.110 |
Why?
|
| Reproductive Behavior | 1 | 2013 | 7 | 0.110 |
Why?
|
| Carcinogenesis | 1 | 2016 | 327 | 0.110 |
Why?
|
| Adipose Tissue | 1 | 2016 | 465 | 0.110 |
Why?
|
| Inheritance Patterns | 1 | 2013 | 125 | 0.110 |
Why?
|
| Mice | 4 | 2023 | 17486 | 0.100 |
Why?
|
| Linkage Disequilibrium | 3 | 2012 | 310 | 0.100 |
Why?
|
| Protein Kinases | 1 | 2014 | 330 | 0.100 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2014 | 340 | 0.100 |
Why?
|
| Animals | 6 | 2023 | 33718 | 0.100 |
Why?
|
| Down-Regulation | 1 | 2014 | 696 | 0.090 |
Why?
|
| Molecular Targeted Therapy | 1 | 2014 | 352 | 0.090 |
Why?
|
| Autoimmune Diseases | 1 | 2013 | 250 | 0.090 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2014 | 428 | 0.090 |
Why?
|
| Fertility | 1 | 2013 | 263 | 0.090 |
Why?
|
| Nerve Tissue Proteins | 1 | 2017 | 1116 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2014 | 490 | 0.090 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2011 | 184 | 0.090 |
Why?
|
| DNA Copy Number Variations | 2 | 2017 | 939 | 0.090 |
Why?
|
| Chromatin | 1 | 2014 | 552 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2017 | 1870 | 0.090 |
Why?
|
| Ganglia, Spinal | 2 | 2020 | 73 | 0.080 |
Why?
|
| Data Interpretation, Statistical | 2 | 2014 | 229 | 0.080 |
Why?
|
| Case-Control Studies | 5 | 2018 | 3251 | 0.080 |
Why?
|
| Genetic Markers | 1 | 2010 | 609 | 0.080 |
Why?
|
| Oxidative Stress | 1 | 2014 | 796 | 0.080 |
Why?
|
| Cell Movement | 2 | 2023 | 831 | 0.070 |
Why?
|
| Body Mass Index | 1 | 2013 | 1541 | 0.070 |
Why?
|
| RNA, Messenger | 1 | 2014 | 2815 | 0.070 |
Why?
|
| MicroRNAs | 1 | 2014 | 827 | 0.070 |
Why?
|
| Neoplasms | 2 | 2018 | 2766 | 0.070 |
Why?
|
| Aged | 7 | 2019 | 19068 | 0.070 |
Why?
|
| Emigration and Immigration | 1 | 2006 | 81 | 0.070 |
Why?
|
| Base Sequence | 1 | 2011 | 3092 | 0.070 |
Why?
|
| Selection, Genetic | 1 | 2006 | 155 | 0.060 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2009 | 254 | 0.060 |
Why?
|
| Demography | 1 | 2006 | 239 | 0.060 |
Why?
|
| Gene Deletion | 1 | 2009 | 793 | 0.060 |
Why?
|
| Computer Graphics | 1 | 2005 | 38 | 0.060 |
Why?
|
| Diploidy | 1 | 2005 | 35 | 0.060 |
Why?
|
| Genetics | 1 | 2005 | 25 | 0.060 |
Why?
|
| Time | 1 | 2005 | 94 | 0.060 |
Why?
|
| Middle Aged | 7 | 2019 | 25964 | 0.060 |
Why?
|
| Female | 11 | 2019 | 65443 | 0.060 |
Why?
|
| Fluorouracil | 1 | 2004 | 128 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2004 | 353 | 0.050 |
Why?
|
| Male | 9 | 2019 | 60034 | 0.050 |
Why?
|
| Doxorubicin | 1 | 2004 | 301 | 0.050 |
Why?
|
| Cluster Analysis | 2 | 2017 | 400 | 0.050 |
Why?
|
| Neoadjuvant Therapy | 1 | 2004 | 321 | 0.050 |
Why?
|
| Obesity | 1 | 2013 | 2226 | 0.050 |
Why?
|
| Cyclophosphamide | 1 | 2004 | 420 | 0.050 |
Why?
|
| Polysaccharides | 1 | 2023 | 143 | 0.050 |
Why?
|
| Mice, Knockout | 2 | 2020 | 3715 | 0.050 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2023 | 215 | 0.050 |
Why?
|
| Lung Neoplasms | 2 | 2014 | 1580 | 0.050 |
Why?
|
| Proteomics | 1 | 2004 | 479 | 0.040 |
Why?
|
| Gene Expression Profiling | 2 | 2017 | 1680 | 0.040 |
Why?
|
| Meninges | 1 | 2020 | 16 | 0.040 |
Why?
|
| Sciatic Nerve | 1 | 2020 | 54 | 0.040 |
Why?
|
| Peripheral Nerve Injuries | 1 | 2020 | 33 | 0.040 |
Why?
|
| Models, Biological | 1 | 2005 | 1441 | 0.040 |
Why?
|
| Nerve Fibers | 1 | 2019 | 71 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2020 | 4268 | 0.040 |
Why?
|
| Isotopes | 1 | 2019 | 27 | 0.040 |
Why?
|
| Neoplasms, Adnexal and Skin Appendage | 1 | 2018 | 5 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2019 | 254 | 0.040 |
Why?
|
| Epidermal Cyst | 1 | 2018 | 19 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2019 | 271 | 0.040 |
Why?
|
| Regression Analysis | 2 | 2011 | 773 | 0.040 |
Why?
|
| Leukocytes | 1 | 2020 | 207 | 0.040 |
Why?
|
| Chromatography, Liquid | 1 | 2019 | 191 | 0.040 |
Why?
|
| Chronic Pain | 1 | 2020 | 127 | 0.040 |
Why?
|
| Papillomaviridae | 1 | 2018 | 137 | 0.040 |
Why?
|
| Adult | 5 | 2018 | 29029 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2004 | 1230 | 0.040 |
Why?
|
| Sequence Analysis, Protein | 1 | 2017 | 49 | 0.040 |
Why?
|
| Mutation Rate | 1 | 2017 | 66 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2018 | 6372 | 0.030 |
Why?
|
| Receptors, Notch | 1 | 2018 | 202 | 0.030 |
Why?
|
| Bacteriophage phi X 174 | 1 | 2016 | 4 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2020 | 528 | 0.030 |
Why?
|
| K562 Cells | 1 | 2016 | 95 | 0.030 |
Why?
|
| Phenotype | 2 | 2017 | 4221 | 0.030 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2019 | 422 | 0.030 |
Why?
|
| Cloud Computing | 1 | 2015 | 10 | 0.030 |
Why?
|
| Polymyositis | 1 | 2015 | 7 | 0.030 |
Why?
|
| Janus Kinase 2 | 1 | 2016 | 136 | 0.030 |
Why?
|
| Stromal Cells | 1 | 2016 | 294 | 0.030 |
Why?
|
| Time Factors | 1 | 2005 | 6205 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2017 | 793 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2018 | 868 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 1305 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2017 | 471 | 0.030 |
Why?
|
| DNA, Viral | 1 | 2016 | 477 | 0.030 |
Why?
|
| STAT3 Transcription Factor | 1 | 2016 | 216 | 0.030 |
Why?
|
| Recurrence | 1 | 2018 | 1422 | 0.030 |
Why?
|
| Molecular Epidemiology | 1 | 2014 | 156 | 0.030 |
Why?
|
| Linear Models | 1 | 2016 | 670 | 0.030 |
Why?
|
| Sample Size | 1 | 2014 | 84 | 0.030 |
Why?
|
| Open Reading Frames | 1 | 2014 | 211 | 0.030 |
Why?
|
| Haplotypes | 1 | 2015 | 519 | 0.030 |
Why?
|
| Adolescent | 3 | 2018 | 19093 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2018 | 3329 | 0.030 |
Why?
|
| Multifactorial Inheritance | 1 | 2014 | 137 | 0.030 |
Why?
|
| Monte Carlo Method | 1 | 2013 | 92 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2018 | 1170 | 0.030 |
Why?
|
| Transcriptome | 1 | 2019 | 908 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2011 | 2024 | 0.030 |
Why?
|
| Probability | 1 | 2013 | 322 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2016 | 1012 | 0.030 |
Why?
|
| Risk Factors | 2 | 2018 | 10011 | 0.030 |
Why?
|
| Autoantibodies | 1 | 2015 | 420 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2004 | 2486 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 1873 | 0.020 |
Why?
|
| Neurons | 1 | 2019 | 1927 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2009 | 145 | 0.020 |
Why?
|
| Texas | 1 | 2017 | 3545 | 0.020 |
Why?
|
| Family Health | 1 | 2009 | 259 | 0.020 |
Why?
|
| Prognosis | 1 | 2017 | 4505 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2016 | 4344 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2017 | 12116 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2005 | 62 | 0.020 |
Why?
|
| Likelihood Functions | 1 | 2005 | 112 | 0.020 |
Why?
|
| Research Design | 1 | 2009 | 687 | 0.020 |
Why?
|
| Melanoma | 1 | 2011 | 823 | 0.010 |
Why?
|
| Radiography, Thoracic | 1 | 2005 | 156 | 0.010 |
Why?
|
| Young Adult | 1 | 2018 | 8864 | 0.010 |
Why?
|
| Mastectomy | 1 | 2004 | 63 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2004 | 122 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2004 | 229 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2004 | 730 | 0.010 |
Why?
|
| Postoperative Care | 1 | 2004 | 293 | 0.010 |
Why?
|
| Preoperative Care | 1 | 2004 | 350 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2019 | 16000 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2004 | 1469 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2004 | 1213 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2005 | 2043 | 0.010 |
Why?
|